OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427… http://healthmedicinet.com/i/oncogenex-plans-to-initiate-ogx-42-phase-2-trial-in-patients-with-advanced-squamous-cell-lung-cancer/
Thursday, May 23, 2013
OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment